loading...| Preferred Name |
Idelalisib |
|
| Synonyms |
Phosphoinositide-3 Kinase Delta Inhibitor CAL-101 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one CAL-101 GS 1101 GS-1101 IDELALISIB Idelalisib Zydelig |
|
| Definitions |
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C78825 |
|
| Accepted_Therapeutic_Use_For |
relapsed chronic lymphocytic leukemia (CLL) |
|
| CAS_Registry |
870281-82-6 |
|
| code |
C78825 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. |
|
| Display_Name |
Idelalisib |
|
| FDA_UNII_Code |
YG57I8T5M0 |
|
| FULL_SYN |
Phosphoinositide-3 Kinase Delta Inhibitor CAL-101 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one CAL-101 GS 1101 GS-1101 IDELALISIB Idelalisib Zydelig |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Idelalisib |
|
| Legacy Concept Name |
PI3K-delta_Inhibitor_CAL-101 |
|
| Maps_To |
Idelalisib |
|
| NCI_Drug_Dictionary_ID |
601486 |
|
| PDQ_Closed_Trial_Search_ID |
601486 |
|
| PDQ_Open_Trial_Search_ID |
601486 |
|
| Preferred_Name |
Idelalisib |
|
| prefixIRI |
Thesaurus:C78825 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2698692 |
|
| subClassOf |